VEGFA and hepatocellular carcinoma: Supported by clinical and preclinical evidence, Lenvatinib targets VEGF and FGFR pathways critical for HCC progression, as demonstrated by Suyama and Iwase (2018) and confirmed by the phase III REFLECT trial (Watanabe and Koyama, 2019; Kim et al., 2020).